Foveal Development After Use of Bevacizumab for Aggressive Posterior Retinopathy of Prematurity
Copyright 2019, SLACK Incorporated.
| Veröffentlicht in: | Ophthalmic surgery, lasers & imaging retina. - 2013. - 50(2019), 6 vom: 01. Juni, Seite e185-e187 |
|---|---|
| 1. Verfasser: | |
| Weitere Verfasser: | , , , |
| Format: | Online-Aufsatz |
| Sprache: | English |
| Veröffentlicht: |
2019
|
| Zugriff auf das übergeordnete Werk: | Ophthalmic surgery, lasers & imaging retina |
| Schlagworte: | Case Reports Journal Article Angiogenesis Inhibitors Bevacizumab 2S9ZZM9Q9V |
| Zusammenfassung: | Copyright 2019, SLACK Incorporated. Foveal development can occur after intravitreal bevacizumab (IVB) treatment for aggressive posterior retinopathy of prematurity (APROP). A 1,310 g male twin, born at 31 weeks, was diagnosed with APROP and undeveloped fovea at 33 weeks. IVB was injected in both eyes. Unfortunately, multiple surgical interventions were required to treat retinal detachment in the left eye, at which time, foveal development was studied in the right eye. Imaging revealed development of foveal capillary ring, avascular zone, and shallow pit. Although bevacizumab is an inhibitor of angiogenesis and delays vascular advancement, development of foveal capillary vascular network with foveal avascular zone and pit can proceed despite multiple treatments. [Ophthalmic Surg Lasers Imaging Retina. 2019;50:e185-e187.] |
|---|---|
| Beschreibung: | Date Completed 15.01.2020 Date Revised 15.01.2020 published: Print Citation Status MEDLINE |
| ISSN: | 2325-8179 |
| DOI: | 10.3928/23258160-20190605-14 |